Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment

Next Previous
X
Search
Trial Profile

A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Acute myeloid leukaemia; Biliary cancer; Breast cancer; Cancer; Chronic myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Malignant melanoma; Multiple myeloma; Neurofibromatosis 1; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors Array BioPharma; Novartis

    • Most Recent Events

    • 17 Sep 2021 Results assessing the effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of Binimetinib in subjects with hepatic impairment, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
    • 09 Mar 2017 Status changed from recruiting to discontinued.
    • 30 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Mar 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top